TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3304028

Group type: EXPERIMENTAL
Intervention: Oral clonidine (400 micrograms/day) for twelve weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for twelve weeks
Number of subjects: 10
Study: 30287612

Group type: EXPERIMENTAL
Intervention: Intervention game (SAGA) played for 30 minutes, three times a week
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 34
Study: 27736760

Group type: EXPERIMENTAL
Intervention: 100 mg intravenous (i.v.) omadacycline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 mg oral tablet formulation of omadacycline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 mg oral solution of omadacycline
Number of subjects: 24
Study: 25461357

Group type: EXPERIMENTAL
Intervention: Continuous intra-peritoneal wash with lactated Ringer's for 48 hours
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine intra-operative irrigation
Number of subjects: 52
Study: 22732263

Group type: EXPERIMENTAL
Intervention: Erlotinib alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Erlotinib plus sulindac
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 20417011

Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis (DO) using rigid external distraction (RED) with retention plates
Number of subjects: 13

Group type: COMPARATOR
Intervention: Le Fort I osteotomy (LF1)
Number of subjects: 13
Study: 18701647

Group type: EXPERIMENTAL
Intervention: CMRI vaccine (0.3 to 60 microg followed by a booster dose of 30 microg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMRI vaccine (priming doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMRI vaccine (after booster dose)
Number of subjects: 0
Study: 16081857

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily (n=17)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (n=21)
Number of subjects: 38
Study: 12160502

Group type: EXPERIMENTAL
Intervention: Intrathecal narcotics (morphine and fentanyl)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Epidural analgesia (continuous infusion of bupivacaine and fentanyl)
Number of subjects: 82
Study: 10432467

Group type: EXPERIMENTAL
Intervention: Active transdermal nicotine patch (22 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo transdermal nicotine patch
Number of subjects: 19

Group type: COMPARATOR
Intervention: Both active and placebo patches
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dropouts (not specified intervention)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Completers (not specified intervention)
Number of subjects: 19
Study: 7586920

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1692755

Group type: EXPERIMENTAL
Intervention: Caffeine 450 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 7239899

Group type: EXPERIMENTAL
Intervention: hand-warming treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: hand-cooling treatment
Number of subjects: 13
Study: 31960398

Group type: EXPERIMENTAL
Intervention: Mobile health care intervention for 12 weeks
Number of subjects: 129
Study: 30817090

Group type: EXPERIMENTAL
Intervention: Abdominal massage (5 minutes per session, 3 sessions per day, total of 6 sessions over 2 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no abdominal massage)
Number of subjects: 90
Study: 30400684

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 60
Study: 26037156

Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 24548627

Group type: EXPERIMENTAL
Intervention: Anti-TNF-α therapy
Number of subjects: 8971

Group type: EXPERIMENTAL
Intervention: Anti-TNF-α antibodies (monoclonal and polyclonal)
Number of subjects: 8971

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies
Number of subjects: 8971

Group type: EXPERIMENTAL
Intervention: Polyclonal antibodies or receptor blockers
Number of subjects: 8971

Group type: EXPERIMENTAL
Intervention: Anti-TNF-α therapy in patients with high levels of IL-6 (> 1000 pg/ml)
Number of subjects: 8971

Group type: EXPERIMENTAL
Intervention: Anti-TNF-α therapy in patients with shock
Number of subjects: 8971
Study: 22946985

Group type: EXPERIMENTAL
Intervention: Training village volunteers on the use of Paracheck‐Pf® RDT and ACT (artemether‐lumefantrine)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 38

Group type: COMPARATOR
Intervention: MW group (villages with midwives)
Number of subjects: 38
Study: 19589894

Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study: 17558362

Group type: EXPERIMENTAL
Intervention: Instructions to move the arms out‐of‐phase at each velocity level
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Instructions to move the arms in‐phase at each velocity level
Number of subjects: 8

Group type: COMPARATOR
Intervention: No upper extremity phase manipulation
Number of subjects: 8
Study: 16885421

Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthosis (AFO)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Odstock Dropped-Foot Stimulator (ODFS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No device
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Comparison between AFO and ODFS
Number of subjects: 14
Study: 12893845

Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (0.4 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High nicotine cigarette smoking
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo-cocaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low nicotine cigarette smoking
Number of subjects: 24
Study: 10821873

Group type: EXPERIMENTAL
Intervention: High intensity training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Moderate intensity training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control period (12 weeks before training)
Number of subjects: 54
Study: 9678128

Group type: EXPERIMENTAL
Intervention: CTR-05 (50/100/150 micrograms desogestrel and 35/30/30 micrograms ethinylestradiol)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Orthonovum777 (500/750/1000 micrograms norethindrone and 35/35/35 micrograms ethinylestradiol)
Number of subjects: 46
Study: 1679916

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 21
Study: 6356318

Group type: EXPERIMENTAL
Intervention: sucralfate (1 g tds 2 h after each meal and 1 g nocte)
Number of subjects: 72

Group type: COMPARATOR
Intervention: cimetidine (200 mg tds and 400 mg nocte)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 72

Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 72
Study: 30690053

Group type: EXPERIMENTAL
Intervention: Focused attention condition (attentive eating)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control condition (normal eating)
Number of subjects: 34
Study: 30290277

Group type: EXPERIMENTAL
Intervention: Real-time video counselling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written materials (control)
Number of subjects: 0
Study: 27162033

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 972

Group type: COMPARATOR
Intervention: Implanted cardioverter-defibrillator
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Postrandomization AF/AT
Number of subjects: 972
Study: 25411141

Group type: EXPERIMENTAL
Intervention: 5 ns Q switched Nd YAG laser
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50 ns Q switched Nd YAG laser
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both lasers
Number of subjects: 10
Study: 22198338

Group type: EXPERIMENTAL
Intervention: Intravenous topotecan 0.5mg/m(2) and cisplatin 30 mg/m(2) given weekly for 6 weeks with pelvic radiation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous topotecan 0.5mg/m(2) and cisplatin 40 mg/m(2) given weekly for 6 weeks with pelvic radiation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 30 mg/m(2) in combination with topotecan 0.5mg/m(2) and pelvic radiation
Number of subjects: 11
Study: 19443125

Group type: EXPERIMENTAL
Intervention: Framycetin 1% cream (Soframycin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Silver sulphadiazine
Number of subjects: 40
Study: 17394651

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point of care testing
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Enhanced communication skills training
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Combination of CRP testing and communication skills training
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: CRP testing
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 400
Study: 15718402

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Men and Women
Number of subjects: 1512
Study: 12015695

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg twice daily)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Vancomycin (1 g twice daily)
Number of subjects: 460
Study: 10501557

Group type: EXPERIMENTAL
Intervention: Auditory oddball task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual oddball task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modality non-specific activations
Number of subjects: 0
Study: 7596886

Group type: EXPERIMENTAL
Intervention: Oral ketamine (10 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 30
Study: 2187344

Group type: EXPERIMENTAL
Intervention: Saline solution amnioinfusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 6253021

Group type: EXPERIMENTAL
Intervention: Guar crispbread combined with wholemeal bread
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bread and soya beans
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Guar crispbread with soya beans
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Soya beans with lentils
Number of subjects: 6

Group type: COMPARATOR
Intervention: Porridge and cornflake breakfasts
Number of subjects: 6
Study: 30885505

Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy (indigo carmine dye [0.2%])
Number of subjects: 741

Group type: COMPARATOR
Intervention: Standard white light colonoscopy
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy
Number of subjects: 741
Study: 28147433

Group type: EXPERIMENTAL
Intervention: Aftercare services including telephone follow-up or home visit, caregivers' education and training of social skills, for 20 months after hospital discharge.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intervention from the MoH perspective
Number of subjects: 120
Study: 26494370

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 24127645

Group type: EXPERIMENTAL
Intervention: High-soy diet
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low-soy diet
Number of subjects: 82
Study: 21411800

Group type: COMPARATOR
Intervention: Placebo loading dose followed by conivaptan continuous i.v. infusion using the ampul formulation (regimen 1)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Conivaptan loading dose followed by continuous i.v. infusion using the ampul formulation (regimen 2)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo loading dose followed by conivaptan continuous i.v. infusion using the premixed formulation (regimen 3)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Conivaptan loading dose followed by continuous i.v. infusion using the premixed formulation (regimen 4)
Number of subjects: 121
Study: 19643834

Group type: EXPERIMENTAL
Intervention: Hand cycle interval training (8-12 weeks)
Number of subjects: 22
Study: 17894831

Group type: EXPERIMENTAL
Intervention: Immediate intervention (four educational sessions during year 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed intervention (four educational sessions during year 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Families attending >= 2 sessions
Number of subjects: 0
Study: 15531219

Group type: EXPERIMENTAL
Intervention: Individuals reporting long-term pain; 12.8 contacts per year to primary health care sector
Number of subjects: 22684

Group type: EXPERIMENTAL
Intervention: Individuals reporting long-term pain; higher frequency of hospital admissions and in-hospital days
Number of subjects: 22684

Group type: COMPARATOR
Intervention: Control group (no pain)
Number of subjects: 22684
Study: 11465987

Group type: EXPERIMENTAL
Intervention: Bolus-Continuous (BC-) group (3 mg base rate/h, 1 mg bolus, 20 min lock out)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bolus (B-) group (no base rate, 1 mg bolus, 10 min lock out)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bolus-Continuous (BC-) group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bolus (B-) group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 9596316

Group type: EXPERIMENTAL
Intervention: Tracheal suctioning (TS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (500 microg) before suctioning
Number of subjects: 13
Study: 7829838

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 3182163

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation with cognitive skill (PMR with Cl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active regeneration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive regeneration
Number of subjects: 0
Study: 31806881

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 108
Study: 29757375

Group type: EXPERIMENTAL
Intervention: Tablet-based consent process
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paper-based consent process
Number of subjects: 20
Study: 28043176

Group type: EXPERIMENTAL
Intervention: Heart2HAART smartphone application
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (directly observed treatment with adherence counseling alone)
Number of subjects: 28
Study: 25200397

Group type: EXPERIMENTAL
Intervention: Spirometry and regular medical review
Number of subjects: 238

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 238
Study: 23738992

Group type: EXPERIMENTAL
Intervention: Intervention (depression care management)
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Minor depression (both intervention and control)
Number of subjects: 1226
Study: 22031267

Group type: COMPARATOR
Intervention: Myo-inositol (0.6 g in soft gel capsule or 2 g in powder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18452885

Group type: EXPERIMENTAL
Intervention: Ivermectin 0.1, 0.2, 0.2, and 0.2 mg/kg
Number of subjects: 816

Group type: COMPARATOR
Intervention: Albendazole 6.7 mg/kg
Number of subjects: 816
Study: 17254459

Group type: EXPERIMENTAL
Intervention: BTX‐A injection guided by electric stimulation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 43
Study: 14675858

Group type: EXPERIMENTAL
Intervention: torasemide
Number of subjects: 237

Group type: COMPARATOR
Intervention: furosemide
Number of subjects: 237
Study: 14598357

Group type: EXPERIMENTAL
Intervention: rBPI(21)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10456402

Group type: EXPERIMENTAL
Intervention: Bullectomy by VATS (n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Axillary thoracotomy (n = 18)
Number of subjects: 38
Study: 9638217

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 18
Study: 2746644

Group type: EXPERIMENTAL
Intervention: Cognitive Self‐Management Training (CSM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Attention Placebo Control
Number of subjects: 41

Group type: COMPARATOR
Intervention: Current Clinic Conditions Control
Number of subjects: 41
Study: 776582

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study: 31496260

Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mitomycin C and intracameral bevacizumab
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study: 31300331

Group type: EXPERIMENTAL
Intervention: Four RTS,S/AS01 doses (four‐dose group)
Number of subjects: 3084

Group type: EXPERIMENTAL
Intervention: Three RTS,S/AS01 doses (three‐dose group)
Number of subjects: 3084

Group type: COMPARATOR
Intervention: Control group (four comparator doses)
Number of subjects: 3084
Study: 28685283

Group type: EXPERIMENTAL
Intervention: Low-energy flux density ESWT (Group A, n=20)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-energy flux density ESWT (Group B, n=21)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (Group C, n=23)
Number of subjects: 64
Study: 25909333

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intensive medical diabetes and weight management (IMWM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LAGB
Number of subjects: 45

Group type: COMPARATOR
Intervention: IMWM
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LAGB and IMWM
Number of subjects: 45
Study: 24002495

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg selenized yeast daily for 48 months)
Number of subjects: 1772

Group type: COMPARATOR
Intervention: Placebo (daily for 48 months)
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 1772

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1772
Study: 21148043

Group type: EXPERIMENTAL
Intervention: Tasocitinib (100 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19639398

Group type: EXPERIMENTAL
Intervention: 4-mm catheter tip
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 8-mm catheter tip
Number of subjects: 65
Study: 17352966

Group type: EXPERIMENTAL
Intervention: Acupressure using wristbands (Sea-Band) for 5 days post-chemotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 36
Study: 15162970

Group type: EXPERIMENTAL
Intervention: Female caregivers
Number of subjects: 868

Group type: COMPARATOR
Intervention: Male caregivers
Number of subjects: 868
Study: 11226090

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) using ReliefBand device at P6 acupoint
Number of subjects: 221

Group type: COMPARATOR
Intervention: Sham control (inactive device at P6 acupoint)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo control (inactive device at dorsal aspect of wrist)
Number of subjects: 221
Study: 10097483

Group type: EXPERIMENTAL
Intervention: School and home-based drug prevention program
Number of subjects: 56
Study: 10146667

Group type: EXPERIMENTAL
Intervention: Health promotion program consisting of mailed health risk assessments, individualized reports, self-management materials, and quarterly newsletters.
Number of subjects: 0
Study: 3042398

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study: 31126960

Group type: EXPERIMENTAL
Intervention: Cy/GVAX+CRS-207 (Arm A)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: CRS-207 (Arm B)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Chemotherapy (Arm C)
Number of subjects: 213
Study: 27386808

Group type: EXPERIMENTAL
Intervention: Home-based telesupervising rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 0
Study: 26442399

Group type: EXPERIMENTAL
Intervention: Desflurane (D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane (S)
Number of subjects: 50
Study: 23740211

Group type: EXPERIMENTAL
Intervention: Topical spray (MedSpray™ tinea pedis 1% w/w)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Topical solution (Lamisil® Once 1% w/w)
Number of subjects: 120
Study: 21041163

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (3.75 g)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cholestyramine (12 g)
Number of subjects: 42
Study: 19247022

Group type: EXPERIMENTAL
Intervention: Lichtenstein hernioplasty
Number of subjects: 99

Group type: COMPARATOR
Intervention: Totally extraperitoneal laparoscopic hernioplasty (TEP)
Number of subjects: 99
Study: 16898431

Group type: EXPERIMENTAL
Intervention: OASIS Mouth Moisturizing Spray
Number of subjects: 144

Group type: COMPARATOR
Intervention: SALIVEZE (commercial control)
Number of subjects: 144
Study: 15037411

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg; n = 18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Continuous conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (5 mg; n = 19)
Number of subjects: 37
Study: 11816438

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 1919

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 1919
Study: 9387952

Group type: EXPERIMENTAL
Intervention: Nebulized morphine 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nebulized morphine 40 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 16